Depo-Provera lawsuits represent a rapidly expanding area of pharmaceutical product liability litigation across the United States, impacting thousands of women who used the popular contraceptive injection. These claims primarily involve medroxyprogesterone acetate, the active hormone in the birth control shot, which has been scientifically linked to a significantly increased risk of developing intracranial meningiomas—a type of tumor that forms in the membranes surrounding the brain and spinal cord. Experts allege that long-term or repeated use of the injection can cause these tumors to grow and press against vital neurological tissues, leading to life-altering conditions such as vision loss, cognitive impairment, chronic seizures, and the need for high-risk cranial surgeries.

The health consequences of a meningioma diagnosis are frequently devastating, requiring aggressive medical interventions, complex neurosurgeries, and extensive rehabilitative care. In many instances, evidence produced in 2026 litigation suggests that manufacturers, including Pfizer, were aware of the hormone-linked tumor risks for years yet failed to update U.S. safety labels until the FDA mandated a warning in late 2025. When such a failure to warn is established, affected individuals may have the legal right to pursue compensation for their medical expenses, lost wages, physical pain, and emotional distress, as well as punitive damages intended to hold pharmaceutical companies accountable for prioritizing profit over women’s long-term health and safety.